Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
TriSalus Life Sciences Inc. (TLSI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: TLSI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Analysis of Past Performance
Type Stock | Historic Profit -4.29% | Avg. Invested days 85 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 172.04M USD | Price to earnings Ratio - | 1Y Target Price 11.44 |
Price to earnings Ratio - | 1Y Target Price 11.44 | ||
Volume (30-day avg) 61221 | Beta 0.48 | 52 Weeks Range 3.50 - 10.42 | Updated Date 04/1/2025 |
52 Weeks Range 3.50 - 10.42 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.31 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -102.09% | Operating Margin (TTM) -91.76% |
Management Effectiveness
Return on Assets (TTM) -90.97% | Return on Equity (TTM) -496.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 187765537 | Price to Sales(TTM) 5.85 |
Enterprise Value 187765537 | Price to Sales(TTM) 5.85 | ||
Enterprise Value to Revenue 6.38 | Enterprise Value to EBITDA -5.96 | Shares Outstanding 31279300 | Shares Floating 22187946 |
Shares Outstanding 31279300 | Shares Floating 22187946 | ||
Percent Insiders 53.57 | Percent Institutions 12.79 |
Analyst Ratings
Rating 4.71 | Target Price 11.64 | Buy 2 | Strong Buy 5 |
Buy 2 | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
TriSalus Life Sciences Inc.
Company Overview
History and Background
TriSalus Life Sciences Inc. is a commercial-stage medical device company dedicated to developing technologies for liver-directed drug delivery. It was founded with the goal of improving outcomes for patients with liver tumors.
Core Business Areas
- Drug Delivery Systems: Development and commercialization of devices for targeted delivery of therapeutics to liver tumors, including pressurized intra-arterial (pIA) drug delivery.
Leadership and Structure
The leadership team includes key executives with expertise in medical device development, commercialization, and clinical research. The organizational structure is designed to support innovation and market expansion.
Top Products and Market Share
Key Offerings
- TriNav Infusion System: A device that delivers regional cancer therapy to the liver using pIA drug delivery. Market share data is still developing given its commercial stage. Key competitors include traditional TACE procedures and other drug delivery methods. No market share or revenue data available.
- Pancreatic Retrograde Venous Infusion (PRVI): An investigational drug-delivery system for pancreatic cancer. No market share or revenue data available. No clear competors for this device exists.
Market Dynamics
Industry Overview
The market for liver cancer therapies is growing due to increasing incidence rates and advancements in treatment options.
Positioning
TriSalus Life Sciences Inc. aims to be a leader in liver-directed drug delivery with its innovative pIA technology. The competitive advantage lies in potentially improving drug penetration and efficacy within liver tumors.
Total Addressable Market (TAM)
The TAM for liver cancer therapies is estimated to be in the billions of dollars globally. TriSalus Life Sciences Inc. is positioned to capture a portion of this market with its targeted drug delivery approach.
Upturn SWOT Analysis
Strengths
- Novel pIA drug delivery technology
- Focus on liver-directed therapies
- Potential to improve drug penetration in tumors
- Strong intellectual property portfolio
Weaknesses
- Limited commercial history
- Dependence on clinical trial results
- Competition from established therapies
- Need for further clinical validation
Opportunities
- Expanding indications for pIA drug delivery
- Partnering with pharmaceutical companies
- Developing new drug-device combinations
- Entering new geographic markets
Threats
- Regulatory hurdles
- Reimbursement challenges
- Competition from other therapies
- Adverse clinical trial outcomes
Competitors and Market Share
Key Competitors
- MRK
- BAYRY
- BMY
Competitive Landscape
TriSalus Life Sciences Inc. faces competition from established pharmaceutical and medical device companies. Its advantage lies in its novel pIA technology, but it needs to demonstrate superior clinical outcomes and gain market share.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is limited due to the company's recent commercialization.
Future Projections: Future growth is dependent on successful clinical trials and market adoption of its products. Analyst estimates vary.
Recent Initiatives: Recent initiatives include expanding clinical trials and building commercial infrastructure.
Summary
TriSalus Life Sciences Inc. is an emerging company with a promising technology for liver-directed drug delivery. Its success hinges on positive clinical trial results and market adoption. The company faces competition from established players and needs to navigate regulatory and reimbursement hurdles. Continued innovation and strategic partnerships will be crucial for its growth.
Similar Companies
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
MRK
Merck & Company Inc
MRK
Merck & Company Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market data is subject to change and accuracy cannot be guaranteed. AI-based ratings are solely opinions based on current information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About TriSalus Life Sciences Inc.
Exchange NASDAQ | Headquaters Westminster, CO, United States | ||
IPO Launch date 2023-08-10 | CEO, President & Director Ms. Mary T. Szela B.S.N., M.B.A. | ||
Sector Healthcare | Industry Medical Devices | Full time employees - | Website https://trisaluslifesci.com |
Full time employees - | Website https://trisaluslifesci.com | ||
TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.